Volume 28, Number 2—February 2022
Research Letter
Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia
Ekaterina Krieger, Alexander Kudryavtsev, Ekaterina Sharashova, Vitaly Postoev, Natalia Belova, Leonid Shagrov, Julia Zvedina, Oxana Drapkina, Anna Kontsevaya, Svetlana Shalnova, Tormod Brenn, Vladimir M. Shkolnikov, Rosalind M. Eggo, and David A. Leon
Table
Seroprevalence of severe acute respiratory syndrome coronavirus 2 in adults, Arkhangelsk, Russia
| Characteristic | Unvaccinated |
Vaccinated* |
Total |
|||||
|---|---|---|---|---|---|---|---|---|
| No. seropositive/total (%) | Adjusted seroprevalence, % (95% CI)† | No. seropositive/total (%) | Adjusted seroprevalence, % (95% CI)† | No. seropositive/total (%) | Adjusted seroprevalence, % (95% CI)† | |||
| Sex | ||||||||
| F | 332/553 (60) | 67.4 (58.4–77.9) | 72/81 (89) | 99.7 (87.1–99.9) | 404/634 (64) | 71.5 (62.6–82.3) | ||
| M |
208/352 (59) |
66.3 (56.5–77.3) |
78/81 (96) |
100 (93.2–100) |
286/433 (66) |
74.1 (64.5–85.6) |
||
| Age, y | ||||||||
| 40–54 | 291/461 (63) | 70.8 (61.4;81.8) | 35/38 (92) | 100 (84.8–100) | 326/499 (65) | 73.3 (64.0–84.6) | ||
| 55–64 | 181/317 (57) | 64.1 (54.1–75.0) | 38/43 (88) | 99.1 (82.6–100) | 219/360 (61) | 68.3 (58.4–79.4) | ||
| >65 |
68/127 (54) |
60.1 (46.9–73.1) |
77/81 (95) |
100 (92.4–100) |
145/208 (70) |
78.2 (67.0–91.2) |
||
| Education | ||||||||
| Secondary and lower | 26/47 (55) | 62.1 (42.7–81.0) | 9/9 (100) | 100 (66.7–100) | 35/56 (63) | 70.1 (52.5–88.1) | ||
| Specialized secondary | 253/433 (58) | 65.6 (56.1–76.0) | 81/87 (93) | 100 (91.2–100) | 334/520 (64) | 72.1 (62.9–83.2) | ||
| Higher |
261/425 (61) |
68.9 (59.3–79.8) |
60/66 (91) |
100 (88.0–100) |
321/491 (65) |
73.3 (64.0–84.6) |
||
| Week of test | ||||||||
| 7–14 | 395/651 (61) | 68.1 (59.3–78,4) | 49/58 (84) | 94.8 (81.0–100) | 444/709 (63) | 70.3 (61.6–80.8) | ||
| 15–21 |
145/254 (57) |
64.0 (53.4–75.3) |
101/104 (97) |
100 (94.8–100) |
246/358 (69) |
77.1 (67.1–89.1) |
||
| Self-reported prior symptoms of infection | ||||||||
| No | 172/477 (36) | 40.5 (31.7–47.8) | 133/143 (93) | 100 (92.9–100) | 305/620 (49) | 55.2 (46.6–64.0) | ||
| Yes | 248/256 (97) | 100 (96.9–100) | 8/9 (89) | 99.7 (56.8–100) | 256/265 (97) | 100 (96.7–100) | ||
| Do not know |
120/172 (70) |
78.3 (66.5–91.6) |
9/10 (90) |
100 (60.4–100) |
129/182 (71) |
79.5 (68.1–92.8) |
||
| Total | 540/905 (60) | 66.9 (58.6–76.9) | 150/162 (93) | 100 (92.9–100) | 690/1067 (65) | 72.6 (64.2–83.1) | ||
*Received >1 dose. †Values >100% were rounded to 100%. ‡Weeks 7–14 are February 24–April 11 and weeks 15–21 are April 12–May 28, 2021.
Page created: December 08, 2021
Page updated: January 22, 2022
Page reviewed: January 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.